Business
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting
GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting.
About this update from Rebus Hldgs Inc.
[{"type":"text","content":"\n \n \n GenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting\n \n \nGenSpera Phase II Abstract Accepted for Presentation at the Society of Neuro-Oncology 20th Annual Scientific Meeting\n \n SAN ANTONIO, TX--(Marketwired - Jul 28, 2015) - GenSpera, Inc. (OTCQB: GNSZ) announced today that the Society for Neuro-Oncology and the 2015 Scientific Program Committee has accepted an abstract for presentation at the Society for Neuro-Oncology's 20th Annual Scientific Meeting. The abstract is titled: \"Phase II study of mipsagargin (G-202), a PSMA-activated prodrug targeting the tumor endothelium, in adult patients with recurrent or progressive glioblastoma,\" and will be presented during the annual meeting in San Antonio, Texas, between November 19-22, 2015. The two-stage, single-arm, open-label study (NCT02067156) is led by David Piccioni, M.D., Ph.D. and Santosh Kesari, M.D., Ph.D. at the UC San Diego Moores Cancer Center in La Jolla, CA, and will evaluate the efficacy, safety and central nervous system (CNS) exposure in patients with recurrent or progressive glioblastoma. \n About Mipsagargin\n Mipsagargin is a prodrug in human clinical trials for several different tumor types. Mipsagargin consists of a thapsigargin derivative, 12ADT, coupled to a peptide that helps solubilize the prodrug and prevents its internalization into cells until the peptide is removed. The mechanism of action targets the enzyme PSMA, which is highly expressed on the surface of almost all cancer tumor vasculature, including those of glioblastoma. PSMA recognizes and removes the peptide, releasing the active ingredient 12ADT into the cell and bringing about cell death. The prodrug delivery system ensures that mipsagargin is activated only within the tumor, thus providing greater anti-tumor efficacy and minimizing side effects.\n About Glioblastoma\n Glioblastoma is the most common and most aggressive malignant primary brain tumor in humans. There are approximately 10,000 new cases of malignant glioblastoma diagnosed each year in the United States and, despite optimal treatment, the median survival for these patients is only 12 - 15 months. Treatment commonly consists of surgery followed by radiation and the drug temozolomide. A few drugs have been approved in patients that have recurrent tumor...